Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. has been approved for listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant milestone for the company in the medical imaging sector [1] Company Overview - Jianxin Superconducting focuses on the research and production of core components for medical magnetic resonance imaging (MRI), establishing a product matrix that covers both "superconducting + permanent magnet" technologies and mainstream field strengths of "1.5T-3.0T" [1] - The company has become a leading independent supplier of superconducting magnets globally and the largest supplier of permanent magnets for MRI equipment, supporting the upgrade of domestic MRI devices from "usable" to "high-quality" [1] Technological Advancements - In the high-field superconducting magnet sector (1.5T and above), Jianxin Superconducting is one of the earliest manufacturers in China to achieve large-scale production [1] - The company has developed core technologies such as electromagnetic field design, ultra-low temperature technology, and magnet stability control through independent research and development [1] - Jianxin Superconducting has achieved mass supply of zero-evaporation superconducting magnets, significantly enhancing the localization rate of MRI equipment and making a critical breakthrough in entering the supply chain of leading complete machine enterprises [1] Product Offerings - The company can provide over 30 types of permanent magnets and matching gradient coils with magnetic field strengths ranging from 0.08T to 0.5T [1]

Group 1: Company Overview - Hangzhou Lianchuan Biotechnology Co., Ltd. (Lianchuan Bio) has submitted an IPO application to the Beijing Stock Exchange, aiming to raise 300 million yuan, significantly reduced from the previous 608 million yuan planned for the Sci-Tech Innovation Board [1][3] - Lianchuan Bio focuses on the field of genetic technology, providing advanced research services and solutions based on high-throughput sequencing and bioinformatics technology [3][4] - The company has developed innovative gene detection medical devices, integrating basic research with clinical applications [3] Group 2: Financial Performance - As of December 31, 2024, Lianchuan Bio's total assets are projected to be approximately 771.54 million yuan, with total equity of about 536.42 million yuan [5] - The company reported a net profit of approximately 60.06 million yuan for the year ending December 31, 2024, with a gross profit margin of 48.73% [5] - The weighted average return on equity is expected to be 11.87% for 2024, with basic earnings per share projected at 1.29 yuan [5] Group 3: Use of Proceeds - The funds raised from the IPO will be allocated to three main projects: expansion and upgrade of the genetic technology product and service platform (20 million yuan), research and development of molecular diagnostic reagents (5 million yuan), and supplementing working capital (5 million yuan) [6] Group 4: Company Overview (Jianxin Superconductor) - Ningbo Jianxin Superconductor Technology Co., Ltd. specializes in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, including superconducting magnets and gradient coils [8] - The company is one of the earliest manufacturers in China to produce high-field superconducting magnets at scale, breaking the long-standing monopoly of foreign companies [8][9] - Jianxin Superconductor aims to raise funds through an IPO, with a target of issuing up to 41.92 million shares [9] Group 5: Financial Performance (Jianxin Superconductor) - For the year ending December 31, 2024, Jianxin Superconductor's total assets are projected to be approximately 671.28 million yuan, with a net profit of about 55.78 million yuan [10] - The company has a projected gross profit margin of 12.28% and basic earnings per share of 0.44 yuan for 2024 [10] Group 6: Use of Proceeds (Jianxin Superconductor) - The IPO proceeds will be used for several projects, including the production of 600 sets of non-liquid helium superconducting magnets (27.5 million yuan), upgrading the production of high-field medical superconducting magnets (26 million yuan), and research on new superconducting magnets (24 million yuan) [11]